CDER Takes A Micro/Macro Approach To Monitoring ‘Breakthrough’ Programs
Executive Summary
Agency staff will conduct high-level reviews every three to six months to assess adequacy of individual development programs, while the Medical Policy Council will undertake portfolio reviews across breakthrough-designated products.